Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives
-
By
-
B. Nolan
-
C. O’Connor
-
May 9, 2026
Clinical Report: Management Strategies for Infantile Haemangiomas
Overview
Infantile haemangiomas (IH) are prevalent benign vascular tumors that often regress spontaneously, yet 10-15% necessitate intervention due to complications such as ulceration, functional compromise, or disfigurement. Propranolol is established as the first-line treatment, demonstrating significant efficacy and safety. Emerging strategies such as teledermatology enhance access to care.
Background
Infantile haemangiomas are the most common benign vascular tumors in children, affecting 5-10% of white infants and fewer in other ethnic groups, particularly those who are female or born prematurely. While many cases resolve without treatment, a significant minority require intervention due to complications like ulceration or disfigurement. Understanding effective management strategies is crucial for optimizing patient outcomes.
Data Highlights
No numerical data provided in the article.
Key Findings
- Propranolol is the gold standard first-line therapy for problematic IH, with a strong efficacy profile.
- 10-15% of IH cases require treatment due to complications such as ulceration and functional compromise.
- Atenolol and nadolol are viable alternatives to propranolol, potentially reducing adverse effects in selected cases.
- Topical timolol is effective only for small superficial lesions and carries a risk of systemic absorption.
- Teledermatology can improve access to specialists and reduce unnecessary healthcare visits.
Clinical Implications
Clinicians should prioritize early identification and treatment of high-risk infantile haemangiomas to prevent complications. Propranolol should be the first-line treatment, with consideration for alternative beta-blockers in specific cases. Monitoring for adverse effects is essential. Utilizing teledermatology can streamline referrals and enhance patient care.
Conclusion
Propranolol remains the cornerstone of treatment for infantile haemangiomas, with emerging strategies improving access to care. Continued emphasis on early intervention and monitoring is essential for optimal outcomes.
References
- Frontiers in Pediatrics, 2026 -- Systemic propranolol and topical moist wound dressings for ulcerated infantile hemangioma of the scrotum: a case report
- Brain, 2023 -- Response: Management Approaches for Brainstem Cavernous Malformations: Observation, Surgical Resection, or Stereotactic Radiosurgery
- The ASCO Post, 2017 -- Pigmented Vascular Tumor
- Innovations in the Study and Treatment of Cerebrospinal Cavernous Malformations, 2024
- Classification | International Society for the Study of Vascular Anomalies, 2024
- NEJM Clinician, 2015 -- A Randomized, Controlled Trial of Oral Propranolol for Infantile Hemangioma
- JAMA Otolaryngology, 2023 -- Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial
- International Society for the Study of Vascular Anomalies
- A Randomized, Controlled Trial of Oral Propranolol for Infantile Hemangioma | NEJM Clinician
- Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial | Otolaryngology | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
